Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Tina Damgaard, Lene M. Knudsen, Inger Marie S. Dahl, Peter Gimsing, Marianne Lodahl & Thomas Rasmussen. (2009) Regulation of the CD56 promoter and its association with proliferation, anti-apoptosis and clinical factors in multiple myeloma. Leukemia & Lymphoma 50:2, pages 236-246.
Read now
Read now
Articles from other publishers (17)
Yunlu Jia, Jianbiao Zhou, Tze King Tan, Tae-Hoon Chung, Regina Wan Ju Wong, Jing-Yuan Chooi, Julia Sze Lynn Lim, Takaomi Sanda, Melissa Ooi, Sanjay De Mel, Cinnie Soekojo, Yongxia Chen, Enfan Zhang, Zhen Cai, Peng Shen, Jian Ruan & Wee-Joo Chng. (2021) Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma. Blood Cancer Journal 11:2.
Crossref
Crossref
Yujia Xu, Tong Sun, Kun Zeng, Min Xu, Jinhao Chen, Xiaofeng Xu, Zubin Zhang, Biyin Cao, Xiaowen Tang, Depei Wu, Yan Kong, Yuanying Zeng & Xinliang Mao. (2020) Anti-bacterial and anti-viral nanchangmycin displays anti-myeloma activity by targeting Otub1 and c-Maf. Cell Death & Disease 11:9.
Crossref
Crossref
Xue-han Chen, Yu-jia Xu, Xiao-ge Wang, Peng Lin, Bi-yin Cao, Yuan-ying Zeng, Qi Wang, Zu-bin Zhang, Xin-liang Mao & Tie Zhang. (2019) Mebendazole elicits potent antimyeloma activity by inhibiting the USP5/c-Maf axis. Acta Pharmacologica Sinica 40:12, pages 1568-1577.
Crossref
Crossref
GuoQing Wei, LiJun Wang, HanJin Yang, XiaoYan Han, GaoFeng Zheng, WeiYan Zheng, Jie Sun, JiMin Shi, WenJun Wu, Yi Zhao, DongHua He, Bo Wang, Zhen Cai & JingSong He. (2017) Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma. Experimental Hematology & Oncology 6:1.
Crossref
Crossref
Charlotte Pawlyn & Gareth J. Morgan. (2017) Evolutionary biology of high-risk multiple myeloma. Nature Reviews Cancer 17:9, pages 543-556.
Crossref
Crossref
Ya-Wei Qiang, Shiqiao Ye, Yu Chen, Amy F. Buros, Ricky Edmonson, Frits van Rhee, Bart Barlogie, Joshua Epstein, Gareth J. Morgan & Faith E. Davies. (2016) MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma. Blood 128:25, pages 2919-2930.
Crossref
Crossref
Giovanni Tonon & Kenneth C. Anderson. 2015. The Molecular Basis of Cancer. The Molecular Basis of Cancer
455
466.e4
.
Amelia A. Langston & Sagar Lonial. 2011. Bortezomib in the Treatment of Multiple Myeloma. Bortezomib in the Treatment of Multiple Myeloma
69
77
.
Hans E. Johnsen, Martin Bøgsted, Tobias W. Klausen, Peter Gimsing, Alexander Schmitz, Erik Kjærsgaard, Tina Damgaard, Pia Voss, Lene M. Knudsen, Anne K. Mylin, Johan Lanng Nielsen, Bo Björkstrand, Astrid Gruber, Stig Lenhoff, Kari Remes, Inger Marie Dahl, Kirsten Fogd & Karen Dybkær. (2010) Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma. Cytometry Part B: Clinical Cytometry 78B:5, pages 338-347.
Crossref
Crossref
Yasodha Natkunam, Sara Tedoldi, Jennifer C. Paterson, Shuchun Zhao, Manuel Rodriguez-Justo, Andrew H. Beck, Reiner Siebert, David Y. Mason & Teresa Marafioti. (2009) Characterization of c-Maf Transcription Factor in Normal and Neoplastic Hematolymphoid Tissue and Its Relevance in Plasma Cell Neoplasia. American Journal of Clinical Pathology 132:3, pages 361-371.
Crossref
Crossref
Ev Stralen, R J Leguit, H Begthel, L Michaux, A Buijs, H Lemmens, J M Scheiff, C Doyen, P Pierre, F Forget, H C Clevers & BJEG Bast. (2008) MafB oncoprotein detected by immunohistochemistry as a highly sensitive and specific marker for the prognostic unfavorable t(14;20) (q32;q12) in multiple myeloma patients. Leukemia 23:4, pages 801-803.
Crossref
Crossref
Xinliang MaoA. Keith StewartRose HurrenAlessandro DattiXuegong ZhuYuanxiao ZhuChangxin ShiKyle LeeRodger TiedemannYanina EberhardSuzanne TrudelShengben LiangSeth J. CoreyLisa C. GillisDwayne L. BarberJeffery L. Wrana, Shereen EzzatAaron D. Schimmer. (2007) A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. Blood 110:12, pages 4047-4054.
Crossref
Crossref
Giovanni Tonon. (2007) Molecular Pathogenesis of Multiple Myeloma. Hematology/Oncology Clinics of North America 21:6, pages 985-1006.
Crossref
Crossref
Claudia Ivascu, Reinhold Wasserkort, Ralf Lesche, Jun Dong, Harald Stein, Andreas Thiel & Florian Eckhardt. (2007) DNA methylation profiling of transcription factor genes in normal lymphocyte development and lymphomas. The International Journal of Biochemistry & Cell Biology 39:7-8, pages 1523-1538.
Crossref
Crossref
A K Stewart, P L Bergsagel, P R Greipp, A Dispenzieri, M A Gertz, S R Hayman, S Kumar, M Q Lacy, J A Lust, S J Russell, T E Witzig, S R Zeldenrust, D Dingli, C B Reeder, V Roy, R A Kyle, S V Rajkumar & R Fonseca. (2007) A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 21:3, pages 529-534.
Crossref
Crossref
Luigia Lombardi, Giulia Poretti, Michela Mattioli, Sonia Fabris, Luca Agnelli, Silvio Bicciato, Ivo Kwee, Andrea Rinaldi, Domenica Ronchetti, Donata Verdelli, Giorgio Lambertenghi‐Deliliers, Francesco Bertoni & Antonino Neri. (2006) Molecular characterization of human multiple myeloma cell lines by integrative genomics: Insights into the biology of the disease. Genes, Chromosomes and Cancer 46:3, pages 226-238.
Crossref
Crossref
Sonia Fabris, Luca Agnelli, Michela Mattioli, Luca Baldini, Domenica Ronchetti, Fortunato Morabito, Donata Verdelli, Lucia Nobili, Daniela Intini, Vincenzo Callea, Caterina Stelitano, Luigia Lombardi & Antonino Neri. (2004) Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses. Genes, Chromosomes and Cancer 42:2, pages 117-127.
Crossref
Crossref